MX2012013406A - Variantes de union mejoradas anti-albumina serica. - Google Patents
Variantes de union mejoradas anti-albumina serica.Info
- Publication number
- MX2012013406A MX2012013406A MX2012013406A MX2012013406A MX2012013406A MX 2012013406 A MX2012013406 A MX 2012013406A MX 2012013406 A MX2012013406 A MX 2012013406A MX 2012013406 A MX2012013406 A MX 2012013406A MX 2012013406 A MX2012013406 A MX 2012013406A
- Authority
- MX
- Mexico
- Prior art keywords
- serum albumin
- albumin binding
- improved anti
- binding variants
- variants
- Prior art date
Links
- 102000009027 Albumins Human genes 0.000 title abstract 2
- 108010088751 Albumins Proteins 0.000 title abstract 2
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34651910P | 2010-05-20 | 2010-05-20 | |
| PCT/EP2011/058298 WO2011144751A1 (en) | 2010-05-20 | 2011-05-20 | Improved anti-serum albumin binding variants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012013406A true MX2012013406A (es) | 2012-12-10 |
Family
ID=44352234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012013406A MX2012013406A (es) | 2010-05-20 | 2011-05-20 | Variantes de union mejoradas anti-albumina serica. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9040668B2 (enExample) |
| EP (1) | EP2571900A1 (enExample) |
| JP (1) | JP2013529080A (enExample) |
| KR (1) | KR20130109977A (enExample) |
| CN (1) | CN103003303A (enExample) |
| AU (1) | AU2011254559B2 (enExample) |
| BR (1) | BR112012029280A2 (enExample) |
| CA (1) | CA2799633A1 (enExample) |
| EA (1) | EA201291009A1 (enExample) |
| IL (1) | IL222802A0 (enExample) |
| MX (1) | MX2012013406A (enExample) |
| SG (1) | SG185437A1 (enExample) |
| WO (1) | WO2011144751A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| RU2652783C2 (ru) | 2012-12-21 | 2018-05-03 | Санофи | Двойные агонисты glp1/gip или тройные агонисты glp1/gip/глюкагона |
| EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
| WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
| EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
| EP3974449A1 (en) * | 2015-11-13 | 2022-03-30 | Ablynx NV | Improved serum albumin-binding immunoglobulin variable domains |
| CN115837014A (zh) | 2016-05-18 | 2023-03-24 | 摩登纳特斯有限公司 | 编码松弛素的多核苷酸 |
| IL322519A (en) | 2023-02-17 | 2025-10-01 | Ablynx Nv | Polypeptides that bind to the neonatal fc receptor |
| WO2025021183A1 (zh) * | 2023-07-27 | 2025-01-30 | 上海复宏汉霖生物医药有限公司 | 编码促肾上腺皮质激素的多核苷酸及其相关组合物和方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
| EP1600459A3 (en) | 2002-06-28 | 2005-12-07 | Domantis Limited | Ligand |
| EP1737962B1 (en) | 2004-03-24 | 2010-09-01 | Domantis Limited | Gas1 universal leader |
| US8921528B2 (en) | 2004-06-01 | 2014-12-30 | Domantis Limited | Bispecific fusion antibodies with enhanced serum half-life |
| BRPI0518761A2 (pt) | 2004-12-02 | 2008-12-09 | Domantis Ltd | fusço de droga, conjugado de droga, Ácido nucleico recombinante, construÇço de Ácido nucleico, cÉlula hospedeira, mÉtodo para produzir uma fusço de droga, composiÇço farmacÊutica, droga, mÉtodo de tratamento e/ou prevenÇço de uma condiÇço em um paciente, mÉtodo de retardo ou prevenÇço de progressço de doenÇa, e, mÉtodo para diminuir a absorÇço de alimentos por um paciente |
| US20100047171A1 (en) | 2006-01-24 | 2010-02-25 | Roland Beckmann | Fusion Proteins That Contain Natural Junctions |
| GB0724331D0 (en) * | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
| AU2008259590A1 (en) | 2007-06-06 | 2008-12-11 | Domantis Limited | Methods for selecting protease resistant polypeptides |
| US8877186B2 (en) * | 2007-06-06 | 2014-11-04 | Domantis Limited | Polypeptides, antibody variable domains and antagonists |
| BRPI0819693A2 (pt) | 2007-11-30 | 2020-08-18 | Glaxo Group Limited | Construção de ligação de antígeno, método para tratar um paciente que sofre de câncer ou uma doença inflamatória, sequência de polinucleotídeo, polinucleotídeo, célula hospedeira transformada ou transfectada recombinante, método para produziruma construção de ligação de antígeno, e, composição farmacêutica |
| WO2010094722A2 (en) * | 2009-02-19 | 2010-08-26 | Glaxo Group Limited | Improved anti-serum albumin binding variants |
| WO2010094723A2 (en) * | 2009-02-19 | 2010-08-26 | Glaxo Group Limited | Improved anti-serum albumin binding variants |
| KR20110119806A (ko) | 2009-02-19 | 2011-11-02 | 글락소 그룹 리미티드 | 개선된 항ｔｎｆｒ1 폴리펩티드，항체 가변 도메인 및 길항제 |
| JP2012521971A (ja) * | 2009-03-27 | 2012-09-20 | グラクソ グループ リミテッド | 薬物融合体および複合体 |
| JP2012532619A (ja) * | 2009-07-16 | 2012-12-20 | グラクソ グループ リミテッド | Ｔｎｆｒ１を部分的に阻害するためのアンタゴニスト、用途および方法 |
| CN104147611A (zh) * | 2009-09-30 | 2014-11-19 | 葛兰素集团有限公司 | 具有延长的半衰期的药物融合体和缀合物 |
-
2011
- 2011-05-20 SG SG2012081683A patent/SG185437A1/en unknown
- 2011-05-20 CN CN2011800351661A patent/CN103003303A/zh active Pending
- 2011-05-20 EP EP11720310A patent/EP2571900A1/en not_active Withdrawn
- 2011-05-20 CA CA2799633A patent/CA2799633A1/en not_active Abandoned
- 2011-05-20 BR BR112012029280A patent/BR112012029280A2/pt not_active IP Right Cessation
- 2011-05-20 WO PCT/EP2011/058298 patent/WO2011144751A1/en not_active Ceased
- 2011-05-20 MX MX2012013406A patent/MX2012013406A/es not_active Application Discontinuation
- 2011-05-20 KR KR1020127033268A patent/KR20130109977A/ko not_active Withdrawn
- 2011-05-20 EA EA201291009A patent/EA201291009A1/ru unknown
- 2011-05-20 JP JP2013510643A patent/JP2013529080A/ja active Pending
- 2011-05-20 US US13/698,794 patent/US9040668B2/en not_active Expired - Fee Related
- 2011-05-20 AU AU2011254559A patent/AU2011254559B2/en not_active Ceased
-
2012
- 2012-11-01 IL IL222802A patent/IL222802A0/en unknown
-
2015
- 2015-04-21 US US14/691,913 patent/US20150284454A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EA201291009A1 (ru) | 2013-05-30 |
| BR112012029280A2 (pt) | 2016-11-29 |
| CN103003303A (zh) | 2013-03-27 |
| US20150284454A1 (en) | 2015-10-08 |
| KR20130109977A (ko) | 2013-10-08 |
| US9040668B2 (en) | 2015-05-26 |
| CA2799633A1 (en) | 2011-11-24 |
| IL222802A0 (en) | 2012-12-31 |
| EP2571900A1 (en) | 2013-03-27 |
| WO2011144751A1 (en) | 2011-11-24 |
| AU2011254559A1 (en) | 2013-01-17 |
| US20130129746A1 (en) | 2013-05-23 |
| AU2011254559B2 (en) | 2014-09-04 |
| JP2013529080A (ja) | 2013-07-18 |
| SG185437A1 (en) | 2012-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011008752A (es) | Variantes de union a anti-albumina de suero mejoradas. | |
| MX2012013406A (es) | Variantes de union mejoradas anti-albumina serica. | |
| MX2012000765A (es) | Dominios variables sencillos de union de albumina anti-suero mejorados. | |
| MX2011008749A (es) | Variantes de union a anti-albumina de suero mejoradas. | |
| CY1119567T1 (el) | Θεραπευτικα πεπτιδια | |
| WO2012072731A3 (en) | Improved anti-serum albumin binding single variable domains | |
| WO2014083208A9 (en) | Binding proteins comprising at least two repeat domains against her2 | |
| EA201401254A1 (ru) | Самостабилизирующиеся линкерные конъюгаты | |
| EA201390785A1 (ru) | Антитела, обладающие низкой аффинностью к рецепторам гематоэнцефалического барьера, и их применения | |
| UA106900C2 (uk) | Агоністичний dr5-зв'язувальний поліпептид | |
| NZ700891A (en) | 4-1bb binding molecules | |
| WO2012019024A3 (en) | Her3-binding molecules and immunoconjugates thereof | |
| MX2013002055A (es) | Variantes anti-enlace de albumina de suero mejodas. | |
| AU2015370918A8 (en) | Binding protein drug conjugates comprising anthracycline derivatives | |
| WO2011086143A3 (en) | Liver targeting domain antibodies | |
| EA201290642A1 (ru) | Соединения и способы | |
| NZ700274A (en) | Anti-pdgf-c antibodies | |
| WO2011112566A3 (en) | Basigin binding proteins | |
| CA3036643C (en) | Cmet monoclonal binding agents, drug conjugates thereof and uses thereof | |
| MX2015014198A (es) | Anticuerpos cuyo objetivo es m-csf. | |
| WO2014044793A3 (en) | Cd22-binding peptides | |
| MX2016008478A (es) | Nuevo anticuerpo anti adam17 y su uso en el tratamiento del cancer. | |
| WO2012136792A3 (en) | Cck compositions | |
| CR20110473A (es) | Variantes de union a anti-albúmina de suero mejoradas. | |
| HK1196856A (en) | C10rf32 antibodies, and uses thereof for treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |